PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

Slides:

Advertisements

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Advertisements

Drug concentration (μM)

Platelet-Derived Growth Factor-BB Mediates Cell Migration through Induction of Activating Transcription Factor 4 and Tenascin-C Kristine P. Malabanan,

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.

miR-133a positively regulated p53/p21 pathway.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.

Antiproliferative effects of erlotinib correlate poorly with abundance of p-EGFR. Antiproliferative effects of erlotinib correlate poorly with abundance.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

DNAPKcs is required for DNA repair in the presence of androgen.

NRP2 represses IGF-IR expression and signaling.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Volume 17, Issue 6, Pages (June 2013)

A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer Edward.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

Volume 8, Issue 4, Pages (October 2005)

Volume 4, Issue 4, Pages (August 2013)

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Fig. 2. p85β regulates cell adhesion

Volume 22, Issue 5, Pages (November 2012)

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Curcumin-generated ROS activates Chk1 and Chk2 kinases.

PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.

TFAP2A knockdown inhibits tumor growth in vivo.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

Sensor siRNAs can be used in high-order combinations.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

TFAP2A knockdown inhibits cell growth by targeting HIF-1α signaling.

The AKT–mTOR pathway controls PD-L1 protein expression.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

CRA inhibits the growth of human tumor xenografts in vivo.

EGFR signaling regulates transcription of PDGFRβ gene.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Pdcd4 expression inhibits AP-1 transactivation.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Expression of TGFβ ligands in GBM

In vivo effect of KIN-193 on PTEN-deficient tumors.

MSCs elicit EMT, invasion of carcinoma cells, and increased tumor initiation of xenografts. MSCs elicit EMT, invasion of carcinoma cells, and increased.

NSD2-mediated methylation of PTEN at K349 dictates cellular sensitivity to DNA-damaging agents. NSD2-mediated methylation of PTEN at K349 dictates cellular.

Presentation transcript:

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. A, proliferation of U87-EGFRvIII cells over 4 days treated with erlotinib (5 μmol/L) or PDGF-bb ligand (20 ng/mL) alone or in combination as indicated. Erlotinib was added on day 0 of culture, and PDGF-bb was added daily at 20 ng/mL thereafter. B, growth of U87-EGFRvIII cells transiently transfected with control scrambled siRNA or siEGFRvIII and treated with PDGF-bb as described in A. C and D, growth curve of xenografts subcutaneously implanted with U87-EGFRvIII, U87-EGFRvIII/shPDGFRβ, U87-EGFRvIII kinase dead, or U87-EGFRvIII kinase dead/shPDGFRβ cells as indicated. E, immunoblot of phospho-PDGFRβ and EGFR from lysates harvested on day 24 from tumors as described in C and D. F and G, proliferation of EGFRvIII-expressing patient-derived neurospheres GBM39 and HK-250 treated with erlotinib (5 μm) and PDGFRβ inhibitor AG1295 (3 μmol/L) alone or in combination as indicated. **, P < 0.01; ***, P < 0.001. n.s., no statistical significance. David Akhavan et al. Cancer Discovery 2013;3:534-547 ©2013 by American Association for Cancer Research